This content is from: Premium
RA Capital’s SPAC Merger Bet
The biopharma specialist could be signaling renewed confidence in the overall VC market.
There’s new hope for the flailing SPAC market.The merger last week between the blank-check company Frazier Lifesciences Acquisition Corp. and the clinical-stage biopharma company NewAmsterdam Pharma Holding appears to be in much better financial shape than the usual post-SPAC deal these days.Just 32 percent of Frazier shares were redeemed for
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.